140 related articles for article (PubMed ID: 9060542)
1. Bladder preservation by combined modality therapy for invasive bladder cancer.
Kachnic LA; Kaufman DS; Heney NM; Althausen AF; Griffin PP; Zietman AL; Shipley WU
J Clin Oncol; 1997 Mar; 15(3):1022-9. PubMed ID: 9060542
[TBL] [Abstract][Full Text] [Related]
2. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis.
Bamias A; Tsantoulis P; Zilli T; Papatsoris A; Caparrotti F; Kyratsas C; Tzannis K; Stravodimos K; Chrisofos M; Wirth GJ; Skolarikos A; Mitropoulos D; Constantinides CA; Deliveliotis C; Iselin CE; Miralbell R; Dietrich PY; Dimopoulos MA
Cancer Med; 2016 Jun; 5(6):1098-107. PubMed ID: 27004619
[TBL] [Abstract][Full Text] [Related]
4. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
Efstathiou JA; Bae K; Shipley WU; Kaufman DS; Hagan MP; Heney NM; Sandler HM
J Clin Oncol; 2009 Sep; 27(25):4055-61. PubMed ID: 19636019
[TBL] [Abstract][Full Text] [Related]
5. Bladder-Preserving Trimodality Therapy With Capecitabine.
Lynch C; Sweis RF; Modi P; Agarwal PK; Szmulewitz RZ; Stadler WM; O'Donnell PH; Liauw SL; Pitroda SP
Clin Genitourin Cancer; 2024 Apr; 22(2):476-482.e1. PubMed ID: 38228414
[TBL] [Abstract][Full Text] [Related]
6. Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?
Gofrit ON; Meirovitz A; Frank S; Rabinovich I; Luwisch H; Yutkin V; Neuman T; Hidas G; Duvdevani M; Wygoda M
Cancer Med; 2020 Nov; 9(22):8491-8497. PubMed ID: 32960495
[TBL] [Abstract][Full Text] [Related]
7. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Dahl DM; Karrison TG; Michaelson MD; Pham HT; Wu CL; Swanson GP; Shipley WU; Vuky J; Lee RJ; Zietman AL; Souhami L; Chang BK; Deming RL; Ellerton JA; Sandler HM; Rodgers JP; Feng FY; Efstathiou JA
Eur Urol Oncol; 2024 Feb; 7(1):83-90. PubMed ID: 37442672
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Carcinoma of the Bladder: A Case Report.
Gao P; Li X; He Z; Xu Y; Zhang Z
Res Rep Urol; 2024; 16():137-142. PubMed ID: 38894710
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.
Ai J; Zhang S; Qian Y; Kang L; Zhang L; Zhao J
Cancer Biother Radiopharm; 2024 May; 39(4):318-321. PubMed ID: 38324046
[No Abstract] [Full Text] [Related]
10. Selecting patients for immediate cystectomy.
Shariat SF
Rev Urol; 2007; 9(4):239-41. PubMed ID: 18231621
[No Abstract] [Full Text] [Related]
11. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
Shipley WU; Winter KA; Kaufman DS; Lee WR; Heney NM; Tester WR; Donnelly BJ; Venner PM; Perez CA; Murray KJ; Doggett RS; True LD
J Clin Oncol; 1998 Nov; 16(11):3576-83. PubMed ID: 9817278
[TBL] [Abstract][Full Text] [Related]
12. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB; Yu JB
Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
[TBL] [Abstract][Full Text] [Related]
13. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.
Russell CM; Lebastchi AH; Borza T; Spratt DE; Morgan TM
Bladder Cancer; 2016 Oct; 2(4):381-394. PubMed ID: 28035319
[TBL] [Abstract][Full Text] [Related]
14. Outcome of urinary bladder cancer after combined therapies.
Anghel RM; Gales LN; Trifanescu OG
J Med Life; 2016; 9(1):95-100. PubMed ID: 27974922
[No Abstract] [Full Text] [Related]
15. Outcome of urinary bladder cancer after combined therapies.
Anghel RM; Gales LN; Trifanescu OG
J Med Life; 2016; 9(2):153-9. PubMed ID: 27453746
[TBL] [Abstract][Full Text] [Related]
16. Urinary adverse effects of pelvic radiotherapy.
Liberman D; Mehus B; Elliott SP
Transl Androl Urol; 2014 Jun; 3(2):186-95. PubMed ID: 26813159
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?
Méry B; Falk AT; Assouline A; Trone JC; Guy JB; Rivoirard R; Auberdiac P; Escure JL; Moncharmont C; Moriceau G; Almokhles H; de Laroche G; Pacaut C; Guillot A; Chargari C; Magné N
Int Urol Nephrol; 2015 Jul; 47(7):1129-34. PubMed ID: 25982585
[TBL] [Abstract][Full Text] [Related]
18. Trimodality therapy in bladder cancer: who, what, and when?
Premo C; Apolo AB; Agarwal PK; Citrin DE
Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
